Nyxol demonstrated positive topline results in subjects with night vision disturbances in the phase 3 LYNX-1 pivotal clinical trial, Ocuphire Pharma announced in a press release.
One hundred forty-five subjects who experienced night vision impairment were randomly assigned to receive either Nyxol (0.75% phentolamine ophthalmic solution) or placebo daily for 14 days. The primary endpoint was the gain of 15 letters or more of distance vision improvement on a low contrast chart in dim light, the release said.
Nyxol met the primary endpoint, with a greater percentage of subjects who (Read more...)